Form 4: Repligen Director Buys Shares Via 10b5-1 Plan

Repligen Corporation Director Martin D. Madaus acquired 1,800 shares of common stock at an average price of $112.128 through a pre-arranged trading plan.

Summary

• Martin D. Madaus, a Director of Repligen Corporation (RGEN), reported the acquisition of 1,800 shares of common stock.
• The transaction occurred on August 8, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.
• The shares were purchased at a weighted average price of $112.128 per share, with individual transaction prices ranging from $111.72 to $112.35.
• Following this transaction, Mr. Madaus beneficially owns a total of 7,397 shares of Repligen common stock.
• This total includes 1,800 shares held indirectly by the Martin D. Madaus 2011 Revocable Trust, 5,586 shares held directly, and 11 shares held indirectly by a Spouse Trust.

Sentiment

Score: 7

Explanation: Insider purchase by a director indicates confidence in the company's future prospects, though the transaction size is not exceptionally large.

Positives

• The purchase by a director, Martin D. Madaus, signals management's confidence in Repligen Corporation's future performance and valuation.
• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-planned acquisition strategy.

Future Outlook

NA

Industry Context

This insider purchase is a routine transaction within the biotechnology sector, where management confidence can be a key indicator for investors. It does not directly reflect broader industry trends but rather specific company sentiment.

Related Party Transactions

• The acquisition of 1,800 shares was made indirectly through the Martin D. Madaus 2011 Revocable Trust, which is a related entity to the reporting director.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal of confidence in the company's valuation and future performance.

Key Dates

Recommendation

The purchase of 1,800 shares by a director, while a positive signal of confidence, is not a sufficiently large transaction to warrant a change in investment thesis or a strong buy/sell recommendation. It reinforces a 'hold' position for existing investors.

Keywords

Repligen, RGEN, insider trading, stock purchase, director, Form 4, 10b5-1 plan, biotechnology